Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924115 | 0.86 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAKCNA3HTT | |
| SCHEMBL9924116 | 0.86 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAKCNA3HTT | |
| SCHEMBL4569249 | 0.86 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAKCNA3HTT | |
| SCHEMBL3656107 | 0.84 | KDM4E (0.42) | KDM4EALDH1A1GAAKCNA3SPHK1 | |
| SCHEMBL12425780 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1GAAKCNA3SPHK1 | |
| SCHEMBL9924112 | 0.78 | CHRM4 (0.31) | — | |
| SCHEMBL9278459 | 0.78 | ACHE (0.45) | ALDH1A1TSHRHTT | |
| SCHEMBL16546656 | 0.78 | GNAI3 (0.35) | — | |
| SCHEMBL10032110 | 0.77 | KCNA3 (0.45) | KDM4EALDH1A1GAAKCNA3SPHK1 | |
| SCHEMBL1572854 | 0.77 | POLB (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-03-11 | — | — | US | disclosed |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2018-12-27 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | KDM4E 1313/4885ALDH1A1 3960/4885GAA 611/4885 |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | KDM4E 3894/4885ALDH1A1 381/4885GAA 2129/4885 |
| US-10851058-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | KDM4E 191/4885ALDH1A1 1150/4885GAA 548/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | KDM4E 1410/4885ALDH1A1 3642/4885GAA 892/4885 |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | KDM4E 191/4885ALDH1A1 1150/4885GAA 548/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | KDM4E 679/4885ALDH1A1 4073/4885GAA 3501/4885 |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | KDM4E 679/4885ALDH1A1 4073/4885GAA 3501/4885 |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | KDM4E 191/4885ALDH1A1 1150/4885GAA 548/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | KDM4E 2311/4885ALDH1A1 328/4885GAA 2133/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | KDM4E 191/4885ALDH1A1 1150/4885GAA 548/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | KDM4E 342/4885ALDH1A1 299/4885GAA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.